Mine Esencay

1.1k total citations
10 papers, 861 citations indexed

About

Mine Esencay is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Mine Esencay has authored 10 papers receiving a total of 861 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Genetics. Recurrent topics in Mine Esencay's work include Chemokine receptors and signaling (4 papers), Immune cells in cancer (3 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Mine Esencay is often cited by papers focused on Chemokine receptors and signaling (4 papers), Immune cells in cancer (3 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Mine Esencay collaborates with scholars based in United States and United Kingdom. Mine Esencay's co-authors include David Zagzag, Elizabeth W. Newcomb, Olga Méndez, Yevgeniy Lukyanov, Herman Yee, Li Lan, Majid Ali, Evelyn B. Voura, Michele Pagano and Vincenzo D’Angiolella and has published in prestigious journals such as Nature Reviews Drug Discovery, American Journal Of Pathology and Trends in Cell Biology.

In The Last Decade

Mine Esencay

10 papers receiving 850 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mine Esencay United States 8 361 335 300 295 252 10 861
Olga Méndez Spain 12 336 0.9× 424 1.3× 266 0.9× 363 1.2× 218 0.9× 27 955
Joseph Gallagher United States 4 491 1.4× 395 1.2× 364 1.2× 265 0.9× 174 0.7× 5 901
Svenja Zapf Germany 14 254 0.7× 294 0.9× 270 0.9× 201 0.7× 150 0.6× 17 714
Demirkan Gursel United States 19 270 0.7× 491 1.5× 243 0.8× 284 1.0× 112 0.4× 32 970
Hauke S. Günther Germany 10 304 0.8× 345 1.0× 374 1.2× 258 0.9× 83 0.3× 12 742
Katyayni Vinnakota Germany 8 204 0.6× 306 0.9× 324 1.1× 195 0.7× 448 1.8× 9 885
Tatsuya Takezaki Japan 12 257 0.7× 333 1.0× 269 0.9× 230 0.8× 88 0.3× 23 660
Thant S. Zhu United States 9 534 1.5× 614 1.8× 360 1.2× 365 1.2× 104 0.4× 10 1.1k
Nancy Lemke United States 15 280 0.8× 478 1.4× 286 1.0× 211 0.7× 101 0.4× 21 1.1k
Tiffany Doucette United States 13 348 1.0× 561 1.7× 398 1.3× 396 1.3× 385 1.5× 17 1.2k

Countries citing papers authored by Mine Esencay

Since Specialization
Citations

This map shows the geographic impact of Mine Esencay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mine Esencay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mine Esencay more than expected).

Fields of papers citing papers by Mine Esencay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mine Esencay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mine Esencay. The network helps show where Mine Esencay may publish in the future.

Co-authorship network of co-authors of Mine Esencay

This figure shows the co-authorship network connecting the top 25 collaborators of Mine Esencay. A scholar is included among the top collaborators of Mine Esencay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mine Esencay. Mine Esencay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Esencay, Mine, et al.. (2017). Biomarker strategy in lung cancer. Nature Reviews Drug Discovery. 17(1). 13–14. 5 indexed citations
2.
Esencay, Mine & Bashar Hamad. (2015). The chronic lymphocytic leukaemia market. Nature Reviews Drug Discovery. 14(6). 381–382. 4 indexed citations
3.
Esencay, Mine, Yasmeen Sarfraz, & David Zagzag. (2013). CXCR7 is induced by hypoxia and mediates glioma cell migration towards SDF-1α. BMC Cancer. 13(1). 347–347. 41 indexed citations
4.
D’Angiolella, Vincenzo, Mine Esencay, & Michele Pagano. (2012). A cyclin without cyclin-dependent kinases: cyclin F controls genome stability through ubiquitin-mediated proteolysis. Trends in Cell Biology. 23(3). 135–140. 73 indexed citations
5.
Esencay, Mine, Elizabeth W. Newcomb, & David Zagzag. (2010). HGF upregulates CXCR4 expression in gliomas via NF-κB: implications for glioma cell migration. Journal of Neuro-Oncology. 99(1). 33–40. 54 indexed citations
6.
Méndez, Olga, Jiří Zavadil, Mine Esencay, et al.. (2010). Knock down of HIF-1α in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Molecular Cancer. 9(1). 133–133. 164 indexed citations
7.
Newcomb, Elizabeth W., Yevgeniy Lukyanov, Michelle Alonso‐Basanta, et al.. (2008). Antiangiogenic Effects of Noscapine Enhance Radioresponse for GL261 Tumors. International Journal of Radiation Oncology*Biology*Physics. 71(5). 1477–1484. 19 indexed citations
8.
Zagzag, David, Mine Esencay, Olga Méndez, et al.. (2008). Hypoxia- and Vascular Endothelial Growth Factor-Induced Stromal Cell-Derived Factor-1α/CXCR4 Expression in Glioblastomas. American Journal Of Pathology. 173(2). 545–560. 163 indexed citations
9.
Newcomb, Elizabeth W., Yevgeniy Lukyanov, Tona Schnee, et al.. (2007). The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo. Anti-Cancer Drugs. 18(8). 875–882. 17 indexed citations
10.
Zagzag, David, Yevgeniy Lukyanov, Li Lan, et al.. (2006). Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Laboratory Investigation. 86(12). 1221–1232. 321 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olga Méndez Breakdown of academic impact, for papers by Joseph Gallagher Breakdown of academic impact, for papers by Svenja Zapf Breakdown of academic impact, for papers by Demirkan Gursel Breakdown of academic impact, for papers by Hauke S. Günther Breakdown of academic impact, for papers by Katyayni Vinnakota Breakdown of academic impact, for papers by Tatsuya Takezaki Breakdown of academic impact, for papers by Thant S. Zhu Breakdown of academic impact, for papers by Nancy Lemke Breakdown of academic impact, for papers by Tiffany Doucette
Rankless by CCL
2026